INOVATE

A multicentre prospective biological sample collection and analysis study, which aims to validate circulating Human Papilloma Virus (HPV) DNA as a marker of residual disease in patients with HPV positive oropharyngeal cancer (OPC).

Disease site: Oropharyngeal cancer

Treatment Modality: Chemo-radiotherapy or radiotherapy alone

Status: In follow-up

Study Details

INOVATE is a multicentre prospective biological sample collection and analysis study, which aims to validate circulating Human Papilloma Virus (HPV) DNA as a marker of residual disease in patients with HPV positive oropharyngeal cancer (OPC).

The study recruited 191 patients with confirmed locally advanced oropharyngeal cancer (OPC), comprising 150 HPV+ OPC patients and 41HPV- OPC patients. Participants were candidates for standard of care, either radical radiotherapy alone or chemotherapy and radiotherapy.

Pre-treatment blood samples were collected for all patients and, from consenting HPV+ patients only, weekly during - and where possible weekly for 4 weeks after - radiotherapy or chemo-radiotherapy treatment.

Blood samples continue to be collected for all patients at 6 weeks and 3, 6, 9 and 12 months post treatment.

All patients donated archival formalin fixed paraffin embedded block from biopsies obtained for diagnosis. In HPV+ patients additional blood sample and tissue samples are being collected, when appropriate, at the time of any post radiotherapy surgical procedures and/or biopsies. Participants will be followed up for a total of 12 months following radiotherapy treatment.

 

Further Information

Chief Investigator: Dr Shreerang Bhide, The Institute of Cancer Research/The Royal Marsden NHS Trust

ICR-CTSU Scientific Lead: Dr Maggie Cheang

Study Management Contact: [email protected]

ISRCTN: 32335415

Sponsor: The Institute of Cancer Research

Funding: Medical Research Council Developmental Pathway Funding Scheme

 

Publications and Presentations

There have been no presentations or publications to date.

breast cancer cell
Major trial shows prolonged benefit of olaparib in early-stage inherited breast cancer

12/12/24

One year of treatment with the targeted drug olaparib improves long-term survival in women with high-risk, early-stage breast cancer with mutations in BRCA1 or BRCA2 genes, new results from a major clinical trial show.
See full story
Breast cancer cell spheroid blue and purple
New understanding of aggressive form of breast cancer paves the way for tests and treatments

10/12/24

Scientists have developed a machine learning tool that can predict how an aggressive type of breast cancer will respond to treatment, and when it will return.
See full story